



Post Authorisation Assessments

Dermipred 20 mg Tablets for Dogs

Vm 14966/3080

May 2026	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance. Change in the pharmacovigilance system master file (PSMF) location.
21 October 2025	SRP application to add two new member states.
06 November 2025	Change in legal entity of MA holder from Ceva Animal Health Ltd, Explorer House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, United Kingdom to Ceva Sante Animale, 8 rue de Logrono, 33500 Libourne, France.
19 September 2025	One-off alignment of the product information with version 9.0* of the QRD templates.
21 May 2025	Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance.
09 December 2024	Reduction in the shelf-life from 3 years to 2 years for the finished products packaged in Al/PVC –Al-OPA blisters and change in storage conditions reducing maximum storage temperature from 30C to 25C.
22 December 2022	Change in the re-test period/storage period of the active substance. Submission of a new Ph. Eur. certificate of suitability for an already approved active substance manufacturer.
30 September 2022	Change of MAH address from: Unit 3 Anglo Office Park, White Lion Road, Amersham, Buckinghamshire, HP7 9FB to Explorer House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, United Kingdom.
08 October 2021	Renewal – UK as CMS.
24 December 2019	Change in the invented name of the veterinary medicinal product from Prednisolone Ceva 10 mg tablets for dogs to Dermipred 10 mg tablets for dogs in France.
04 November 2019	Increase in the shelf-life of the finished product as packaged for sale, from 2 years to 3 years.
23 May 2019	Replacement of a site where batch control/testing takes place.
21 February 2018	Repeat Use application to add 3 new member states.
19 September 2017	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS. Change of the back-up procedure of the QPPV of an existing pharmacovigilance system as described in the DDPS.